title: The monitoring medicines project: a multinational pharmacovigilance and public health project.
abstract: The Monitoring Medicines project (MM), funded by the FP-7 EU framework, was carried out between 2009 and 2013 by a consortium of 11 partners. The objectives were to support and strengthen consumer reporting of adverse drug reactions (ADRs); expand the role and scope of national pharmacovigilance centres concerning medication errors; promote improved use of pharmacovigilance data; and develop methods to complement spontaneous reporting. The work was organised into four themes: patient reporting; medication errors; drug dependence, counterfeit and substandard medicines and clinical risk estimation; and active and targeted spontaneous pharmacovigilance. MM differed from some other major pharmacovigilance initiatives by having participants from developing countries in Asia and Africa and in leaning towards public health and communicable diseases. MM brought together stakeholders including WHO, drug regulators, pharmacovigilance centres, consumers, public health and disease specialists and patient safety networks. Resources and methodologies developed directly by, or with support from, MM include electronic systems/tools for consumer ADR reporting and cohort event monitoring; publication by WHO of handbooks on consumer reporting, medication errors and pharmacovigilance for TB medicines; methodologies for detecting drug dependence and substandard or counterfeit medicines in ADR databases; and a database on HIV treatment risks with a risk assessment tool. MM enabled stakeholders to achieve more than if they had worked alone in pursuit of patient safety.
authors.affiliation: Quality Assurance and Safety: Medicines Department of Essential Medicines and Pharmaceutical Policies, WHO, Geneva, Switzerland, pals@who.int.
authors.forename: Shanthi N
authors.initials: SN
authors.lastname: Pal
authors.forename: Sten
authors.initials: S
authors.lastname: Olsson
authors.forename: Elliot G
authors.initials: EG
authors.lastname: Brown
mesh_terms: D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D005062:European Union; D006801:Humans; D038622:Internationality; D008508:Medication Errors / Q000706:statistics & numerical data; D011358:Product Surveillance, Postmarketing / Q000379:methods* / Q000706:statistics & numerical data*; D011634:Public Health; D014944:World Health Organization
references.citation: Drug Saf. 2015 Apr;38(4):383-93
references.pmid: 25537235
references.citation: Drug Saf. 2012 Jan 1;35(1):45-60
references.pmid: 22149419
references.citation: Eur J Clin Pharmacol. 2011 Mar;67(3):319-20
references.pmid: 20972557
references.citation: Drug Saf. 2015 Apr;38(4):329-35
references.pmid: 25698347
references.citation: Drug Saf. 2015 Apr;38(4):373-82
references.pmid: 25687792
references.citation: Drug Saf. 2014 Jun;37(6):409-19
references.pmid: 24748428
references.citation: World Health Organ Tech Rep Ser. 2006;(942):i, 1-21, 23-4 passim
references.pmid: 17373571
references.citation: Drug Saf. 2015 Apr;38(4):365-72
references.pmid: 25808626
references.citation: Drug Saf. 2015 Apr;38(4):395-408
references.pmid: 25749663
references.citation: Drug Saf. 2015 Apr;38(4):337-47
references.pmid: 25627832
references.citation: Int J Risk Saf Med. 2011;23(1):17-29
references.pmid: 21507783
references.citation: Drug Saf. 2015 Apr;38(4):359-64
references.pmid: 25711669
references.citation: Drug Saf. 2015 Apr;38(4):349-57
references.pmid: 25735854
references.citation: Drug Saf. 2013 Feb;36(2):75-81
references.pmid: 23329541